Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast Cancer

Joyce A. OShaughnessy, MD
Published: Thursday, Aug 27, 2015



Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses new developments in molecular profiling in patients with metastatic breast cancer.

O’Shaughnessy discusses a clinical trial examining the efficacy of letrozole in patients with ER-positive metastatic breast cancer with or without dasatinib. Dasatinib was found to be beneficial in terms of improving duration of response, she adds. However, using the phosphoprotein assay, researchers found that activation of the HER3 protein in patients was a poor prognostic factor in benefitting from letrozole.

The group of patients with HER3 expression benefitted from dasatinib in this study. O'Shaughnessy explains that the phosphoprotein assay can be beneficial in determining which patients will benefit from anti-estrogen agents.
 
SELECTED
LANGUAGE


Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses new developments in molecular profiling in patients with metastatic breast cancer.

O’Shaughnessy discusses a clinical trial examining the efficacy of letrozole in patients with ER-positive metastatic breast cancer with or without dasatinib. Dasatinib was found to be beneficial in terms of improving duration of response, she adds. However, using the phosphoprotein assay, researchers found that activation of the HER3 protein in patients was a poor prognostic factor in benefitting from letrozole.

The group of patients with HER3 expression benefitted from dasatinib in this study. O'Shaughnessy explains that the phosphoprotein assay can be beneficial in determining which patients will benefit from anti-estrogen agents.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x